Castle Biosciences (CSTL) Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Castle Biosciences in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CSTL shares.
View CSTL analyst ratings or view top-rated stocks.

4 equities research analysts have issued 12-month price targets for Castle Biosciences' shares. Their CSTL share price forecasts range from $25.00 to $41.00. On average, they anticipate the company's stock price to reach $32.29 in the next year. This suggests a possible upside of 94.3% from the stock's current price.
View analysts price targets for CSTL or view top-rated stocks among Wall Street analysts.

Castle Biosciences' stock was trading at $23.54 at the beginning of the year. Since then, CSTL shares have decreased by 29.4% and is now trading at $16.62.
View the best growth stocks for 2023 here.

Castle Biosciences saw a increase in short interest in September. As of September 15th, there was short interest totaling 833,200 shares, an increase of 16.2% from the August 31st total of 716,800 shares. Based on an average trading volume of 567,700 shares, the short-interest ratio is currently 1.5 days.
View Castle Biosciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our CSTL earnings forecast.

Castle Biosciences, Inc. (NASDAQ:CSTL) announced its earnings results on Wednesday, August, 2nd. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.01) by $0.31. The company had revenue of $50.14 million for the quarter, compared to the consensus estimate of $43.51 million. Castle Biosciences had a negative trailing twelve-month return on equity of 22.57% and a negative net margin of 53.04%.

First Trust Nasdaq Lux Digital Health Solutions ETF holds 98 shares of CSTL stock, representing 0.21% of its portfolio.

Based on aggregate information from My MarketBeat watchlists, some companies that other Castle Biosciences investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), NVIDIA (NVDA), Block (SQ), DexCom (DXCM), QUALCOMM (QCOM), Teladoc Health (TDOC), Applied Materials (AMAT), Incyte (INCY) and Intel (INTC).

(CSTL) raised $50 million in an initial public offering (IPO) on Thursday, July 25th 2019. The company issued 3,300,000 shares at a price of $14.00-$16.00 per share. SVB Leerink and Baird served as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

Castle Biosciences trades on the NASDAQ under the ticker symbol "CSTL."

Shares of CSTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CSTL stock can currently be purchased for approximately $16.62.

Castle Biosciences (NASDAQ:CSTL) has a market capitalization of $445.58 million and generates $137.04 million in revenue each year. The company earns $-67,140,000.00 in net income (profit) each year or ($3.35) on an earnings per share basis.

The company employs 582 workers across the globe.

Castle Biosciences' mailing address is 820 S FRIENDSWOOD DRIVE SUITE 201, FRIENDSWOOD TX, 77546. The official website for the company is castlebiosciences.com. The company can be reached via phone at (866) 788-9007 or via email at ir@castlebiosciences.com.